33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Friedlander, T. W.; Milowsky, M. I.; Bilen, M. A.; Srinivas, S.; McKay, R. R.; Flaig, T. W.; Hoimes, C. J.; Balar, A. V.; Henry, E.; Petrylak, D. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL)
    Meeting Abstract

    LaCasce, A. S.; Dockter, T.; Ruppert, A. S.; Kostakoglu, L.; Schöder, H.; Hsi, E. D.; Bogart, J. A.; Cheson, B. D.; Wagner-Johnston, N. D.; Abramson, J. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study
    Meeting Abstract

    Zalcberg, J. R.; Heinrich, M. C.; George, S.; Bauer, S.; Schoffski, P.; Serrano, C.; Jones, R. L.; Gelderblom, H.; Attia, S.; D'Amato, G. Z.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial
    Meeting Abstract

    Dispenzieri, A.; Krishnan, A. Y.; Arendt, B.; Dasari, S.; Efebera, Y. A.; Geller, N.; Giralt, S.; Hahn, T.; Kohlhagen, M. C.; Landau, H. J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers
    Meeting Abstract

    Ho, A. L.; Posner, M. R.; Niu, J.; Fu, S.; Leidner, R. S.; Pearson, A. T.; Chung, K. Y.; Richardson, D. L.; Wang, D.; Pimentel, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy
    Meeting Abstract

    Ardeshirrouhanifard, S.; Dinh, P. C.; Monahan, P. O.; Fosså, S.; Huddart, R. A.; Fung, C.; Song, Y.; Feldman, D. R.; Hamilton, R. J.; Vaughn, D. J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial
    Meeting Abstract

    D'Amico, A. V.; Xie, W.; McMahon, E.; Loffredo, M.; Medeiros, S.; Joseph, D. J.; Denham, J. W.; Lamb, D. S.; Kumar, P.; Bubley, G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results
    Meeting Abstract

    Ludwig, J. A.; Federman, N. C.; Anderson, P. M.; Macy, M. E.; Riedel, R. F.; Davis, L. E.; Daw, N. C.; Wulff, J.; Kim, A.; Ratan, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations
    Meeting Abstract

    Haddad, R. I.; Adkins, D.; Licitra, L. F.; Bruce, J. Y.; Gillison, M. L.; Ahn, M. J.; Hsieh, C. Y.; Wang, H. M.; Psyrri, A.; Machiels, J. P. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms
    Meeting Abstract

    Hutson, T. E.; Choueiri, T. K.; Motzer, R. J.; Rha, S. Y.; Alyasova, A.; Merchan, J. R.; Gurney, H.; Peer, A.; Takagi, T.; Porta, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save